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Available online 25 August 2017Aim: Chronic heart failure (CHF) is a life-threatening clinical syndrome, partly due to sudden cardiac death (SCD).
Implantable cardioverter deﬁbrillators (ICD) for primary prevention of SCD have improved overall survival of CHF
patients. However, a high percentage of patients never receives appropriate ICD therapy. This prospective
multicentre study evaluated whether cardiac sympathetic activity assessed by 123I-mIBG scintigraphy could be
helpful in selecting patients for ICD implantation.
Materials and methods: 135 stable CHF subjects (age 64.5 ± 9.3 years, 79% male, LVEF 25 ± 6%) referred
for prophylactic ICD implantation were enrolled in 13 institutions. All subjects underwent planar and SPECT
123I-mIBG scintigraphy. Early and late heart-to-mediastinum (H/M) ratio, 123I-mIBG washout (WO) and late
summed scores were calculated. The primary endpoint was appropriate ICD therapy. The secondary endpoint
was deﬁned as the combined endpoint of allﬁrst cardiac events: appropriate ICD therapy, progression of heart fail-
ure (HF) and cardiac death.
Results: During a median follow-up of 30 months (6–68 months), 24 subjects (17.8%) experienced a ﬁrst cardiac
event (appropriate ICD therapy [12], HF progression [6], cardiac death [6]). Late H/M ratio and defect size of
123I-mIBG SPECT were not associated with appropriate ICD therapy. However, late H/M ratio was independently
associated with the combined endpoint (HR 0.135 [0.035–0.517], p= 0.001). Post-hoc analysis showed that the
combination of late H/M ratio (HR 0.461 [0.281–0.757]) and LVEF (HR 1.052 [1.021–1.084]) was signiﬁcantly
associated with freedom of appropriate ICD therapy (p b 0.001).
Conclusion: 123I-mIBG scintigraphy seems to be helpful in selecting CHF subjects who might not beneﬁt from ICD
implantation.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Despite therapeutic improvements the prognosis of chronic heart fail-
ure (CHF) remains unfavorable partly due to sudden cardiac death (SCD).
The introduction of implantable cardioverter deﬁbrillators (ICD) hasadrenergic receptors; CE, com-
t-to-mediastinum; HR, hazard
ter; NT-proBNP, N-terminal pro
ashout.
icine, AcademicMedical Center,
rdam, The Netherlands.
hure).
land Ltd. This is an open access articlimproved overall survival of CHF patients [1,2]. Based on large random-
ized trials, current European guidelines recommend ICD implantation
for primary prevention of fatal arrhythmias in symptomatic CHF subjects
with New York Heart Association (NYHA) class ≥2 under optimal phar-
macological therapy and a left ventricular ejection fraction (LVEF) b35%
[3]. ICDs applied for primary or secondary prevention of SCD reduce the
relative risk of death by 20%. However, three years after ICD implantation
for primary prevention, a remarkably high percentage (65%) of patients
had never received appropriate ICD therapy [4]. Moreover, the risk of
malfunction, (post)operative complications [5] and the relatively high
cost of these devices urges for optimization of current ICD selection
criteria for primary prevention.
Cardiac sympathetic activity can non-invasively be assessed with
meta-iodobenzylguanidine (123I-mIBG) [6]. The past decades,myocardiale under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients [7,8]. A predeﬁned LEHR (low energy high resolution) collimator
derived late heart-to-mediastinum (H/M) ratio b 1.6 has been suggested
to be a predictor of ventricular arrhythmia [9]. Furthermore, decreased
123I-mIBG uptake and increased wash-out (WO) are associated with
increased incidence of SCD or appropriate ICD therapy [10–12]. Most of
these studies have been conducted in various populations, both with
primary and secondary prevention of SCD. In addition, extrapolation of
the obtained data is hampered by the fact that these data were not
corrected for differences in gamma camera-collimators [13]. Therefore,
the aim of this prospective study was to evaluate whether 123I-mIBG
scintigraphy assessed cardiac sympathetic activity could identify
high-risk CHF patients most likely to undergo appropriate ICD therapy
for primary prevention of SCD.
2. Methods
The study was approved by the local institutional review boards and conducted
according to the principles of the International Conference on Harmonization–Good
Clinical Practice. All subjects provided written informed consent before participation.
The study was registered on www.trialregister.nl (registration number NTR2735).
The study started in two institutions in the Netherlands (Academic Medical Center
(AMC) and Onze Lieve Vrouwe Gasthuis with image acquisition at the AMC) with
the expectation to include 300 subjects. Assuming a 10% appropriate ICD response
per year this would result in approximately 60 subjects with an appropriate ICD
therapy at 2-years follow-up. However, a slow inclusion rate at the initial sites
made us decide to expand the number of participating institutions. (see
“Appendix” for list of all participating institutions). Consequently, correction for dif-
ferent gamma camera-collimator combinations was needed. To convert to standard-
ized ME collimator conditions we used conversion coefﬁcients from our previous
studies [13,14]. However despite this effort inclusion rate remained slow and it
was decided to stop the inclusion at 135 patients. From the 334 potential subjects
screened for participation, only 269 subjects were eligible for inclusion. However,
134 subjects could not be included due to logistics (i.e. transportation to hospital
or participating in competing studies (n = 76) or did not give informed consent
(n = 58)).
2.1. Design
All included patients underwent cardiac 123I-mIBG scintigraphy within 2 weeks prior
to ICD implantation and were followed for the occurrence of the primary and secondary
endpoints.
The primary endpoint for this study was appropriate ICD therapy: ICD therapy to
overcome potentially fatal ventricular arrhythmias: i.e. anti-tachycardia pacing (ATP) or
shock triggered by ventricular tachycardia or ﬁbrillation. The secondary endpoint was
deﬁned as the combined endpoint of all ﬁrst cardiac events: appropriate ICD therapy,
progression of heart failure (HF) and cardiac death.
2.2. Subjects
Patients with stable CHF (ischemic or non-ischemic) who were referred for ICD
implantation for primary prevention of SCDwere enrolled between July 2010 andOctober
2015. The inclusion criteria were: 1. LVEF b35%, 2. NYHA functional class II or III, 3.
Pacemaker-naive, 4. Stable and treated with optimal medical therapy for at least
3 months according to the European HF guidelines [3]. Exclusion criteria were: 1. History
of deﬁbrillation to treat a previous ventricular arrhythmic event, 2. History of acute
myocardial infarction within the previous 30 days.
As part of the workup for ICD implantation all subjects underwent complete clinical
evaluation including echocardiography and blood sample analysis.
2.3. 123I-mIBG scintigraphy acquisition and analysis
To block the uptake of free 123I by the thyroid gland, subjects were pretreated
with 250 mg oral potassium iodide 30 min before intravenous (IV) injection of 185
MBq123I-mIBG (Adreview®, GE, Healthcare). Fifteen minutes (early acquisition)
and 4 h (late acquisition) after administration of 123I-mIBG, 10-min planar images
were acquired from an anterior thoracic view (256 × 256 matrix) with the subjects in
supine position. A 20%windowwas centred at 159 keV. Additional SPECT 123I-mIBG im-
ages, without attenuation correction, were acquired after the late planar acquisitions
(128 × 128 matrix).
All 123I-mIBG data were anonymized and sent to the study coordinating centre
(Academic Medical Center, Amsterdam, the Netherlands). Planar data were analysed by
one experienced observer (D.O.V.) blinded to patient data using post-processing software.
Heart-to-mediastinum (H/M) ratio was calculated from planar 123I-mIBG images using
a manually drawn region-of-interest (ROI) over the heart and a ﬁxed rectangular
mediastinal ROI [15]. To correct for differences in gamma camera-collimator combination,
institutional early and late planar H/M ratios were converted to standardized MEcollimator values by using conversion coefﬁcients from our previous 123I-mIBG cross-
calibrated phantom study [13,14]. The washout (WO) was deﬁned by:
WO ¼ early H=M−late H=Mð Þ
early H=Mð Þ
 
100
All late SPECT 123I-mIBG images were analysed by two experienced observers
(B.L.v.E.S. and H.J.V.) blinded to patient data according a previous published protocol
[16]. Summed scores (range 0–68) were derived by the standard 17-segment model and
5-point scoring method [17].
2.4. ICD implantation
After myocardial 123I-mIBG imaging transvenous or subcutaneous ICDs were
implanted in the participating institutions. Testing of sensing, pacing and deﬁbrillation
thresholds was performed according to local protocols. In case of patient eligibility for
cardiac resynchronization therapy (CRT), a combined CRT-D device was implanted.
Settings for detection of ventricular tachycardias or ﬁbrillation were at the discretion of
the implanting physician.
2.5. Clinical follow-up and event adjudication
Follow-up was based on telephone interviews (D.O.V.) and medical records.
All subjects received standard clinical care and were followed up until: 1. subjects death
was conﬁrmed by medical records of the general practitioner; 2. the trial was terminated
(30th of April 2016). The Clinical Adjudication Committee,whosememberswere unaware of
the scintigraphy data, reviewed all data from case record forms and source documents to
conﬁrm occurrence of cardiac events, speciﬁcally: 1. HF progression: increase in NYHA func-
tional class, or admission due to HF progression; 2. Potentially life-threatening arrhythmic
event, including documented episode of spontaneous sustained (30 s) ventricular tachyar-
rhythmia, resuscitated cardiac arrest, or appropriate ICD therapy: ATP or deﬁbrillation); or
3. Cardiac death (further classiﬁed as due to terminal heart failure and SCD).
2.6. Comparison with a historical Japanese CHF cohort
To compare the mortality rate of our study population with other published data we
used a risk model, based on a historical Japanese CHF cohort [18]. This model estimates
the 2-yearsmortality risk based on four variables (NYHA class, age, LVEF and standardized
late H/M ratio). Using the median 2-year mortality of 9%, patients were divided into
2 groups: mortality rate b 9% and ≥9%. Since the Japanese risk model was made using
data from 1990, the effect of ICD therapy was not included and therefore appropriate
ICD therapy was scored as a fatal event. As this mortality risk model assumes complete
2-year follow-up, patients who had a follow-up b2 years and were alive were excluded
for this analysis.
2.7. Statistical analysis
All continuous variables are expressed as mean ± standard deviation. Difference
between groups for continuous data we compared using analysis of variance (ANOVA)
with post-hoc Bonferroni. Efﬁcacy analysis used univariate and multivariate Cox propor-
tional regression hazards models for primary and secondary endpoint using age, NYHA
class, LVEF, early and late standardized H/M ratio, 123I-mIBG WO and SPECT summed
score as variables. Post-hoc analysis was performed for freedom of appropriate ICD thera-
py. Forward elimination determined the combination of variables thatmost inﬂuenced the
time-over-event model. The χ2 test, Cox's proportional hazard regression coefﬁcient and
exponent were used to describe the model and relative contribution of the parameters
to the model. The hazard ratio (HR) expresses the predicted change in hazard for a unit
change in the predictor. A p-value b0.05 was considered to indicate a statistically
signiﬁcant difference. Statistical analyses were performed with SPSS, release 22.0 (SPSS
Inc., Chicago, USA 2003).3. Results
3.1. Subjects
A total of 135 stable CHF patients (79% men, age 64.5 ± 9.3) were
enrolled. Baseline characteristics of the study population are shown in
Table 1A. Almost 60% of the patients had ischemic heart disease. Mean
NYHA class was 2.2 ± 0.4 and mean LVEF was 25.0 ± 6.2%. The mean
early standardized H/M ratio was 2.05 ± 0.39, the late standardized
H/M ratio was 1.79 ± 0.38 and 123I-mIBG WO was 12.4 ± 9.2%. The
mean SPECT summed score was 39.4 ± 15.5.
Table 1
A. Patients characteristics with subgroups appropriated ICD therapy, combined endpoint (CE) and no CE. P-values indicate any possible difference between groups (ICD therapy, CE and no
CE). * = difference between CE and no CE, p= 0.035. NYHA: New York Heart Association, LVEF: left ventricular ejection fraction; BMI: body mass index; ICD: implantable cardioverter
deﬁbrillator, CRT: cardiac resynchronization therapy; CCB: calcium channel blocker; ACE-I: angiotensin converting enzyme-inhibitor; ARB: angiotensin II receptor blockers; MRA:mineral
receptor blocker. B. Two-year events compared with number of events estimated by 2-year risk model.
SCD = sudden cardiac death, HF = heart failure.
A. All (n= 135) Appropriate ICD therapy (n= 12) CE (n= 24) No CE (n= 111) p-Value
Age (years) 64.5 ± 9.3 65.8 ± 6.9 66.4 ± 7.1 64.1 ± 9.6 0.471
Male (%) 106 (79) 10 (83) 21 (88) 85 (77) 0.462
Ischaemic heart disease (%) 80 (59) 9 (75) 16 (67) 64 (58) 0.409
NYHA functional class 0.308
II 104 (77) 8 (67) 16 (67) 88 (79)
III 31 (23) 4 (33) 8 (33) 23 (21)
LVEF (%) 25.0 ± 6.2 26.2 ± 5.8 25.4 ± 6.3 25.0 ± 6.2 0.787
BMI 27.9 ± 4.7 28.1 ± 3.9 29.1 ± 6.0 27.7 ± 4.3 0.364
Systolic blood pressure (mmHg) 127 ± 19 129 ± 18 125 ± 16 128 ± 19 0.828
Diastolisch blood pressure (mmHg) 73 ± 12 77 ± 12 76 ± 10 75 ± 12 0.852
QRS time (ms) 125 ± 21 125 ± 21 117 ± 18 132 ± 32 0.209
ICD type
Subcutaneous (%) 7 (5) 2 (17) 2 (8) 3 (3) 0.065
CRT (%) 56 (41) 3 (25) 10 (42) 45 (41) 0.980
Cardiovascular risk factors
Diabetes (%) 39 (29) 5 (42) 10 (42) 29 (26) 0.330
Hypertension (%) 76 (56) 7 (58) 13 (54) 63 (57) 0.965
Dyslipidemia (%) 56 (42) 7 (58) 12 (50) 44 (40) 0.465
Smoking (%) 34 (25) 3 (25) 11 (46) 23 (21) 0.633
Medication
Beta-blocker (%) 112 (83) 11 (92) 18 (75) 94 (85) 0.379
CCB (%) 12 (9) 3 (25) 4 (17) 8 (7) 0.081
ACE-I/ARB (%) 126 (93) 11 (92) 22 (92) 104 (94) 0.917
Loop diuretic (%) 88 (65) 10 (83) 20 (83) 68 (61) 0.051
MRA(%) 64 (47) 7 (58) 13 (54) 51 (46) 0.594
Asperin (%) 64 (47) 5 (42) 10 (42) 54 (49) 0.770
Statine (%) 86 (64) 9 (75) 15 (63) 71 (64) 0.733
Planar 123I-mIBG
Early H/M ratio 2.04 ± 0.39 2.09 ± 0.27 2.00 ± 0.26 2.06 ± 0.42 0.721
Late H/M ratio 1.79 ± 0.38 1.74 ± 0.20 1.66 ± 0.24 1.82 ± 0.40 0.131
123I-mIBG WO 12.4 ± 9.2 16.2 ± 8.0 16.6 ± 9.2 11.5 ± 8.9 0.017*
Late SPECT 123I-mIBG (n = 111) (n = 12) (n = 22) (n = 89)
Summed score 39.4 ± 15.5 34.9 ± 13.1 37.4 ± 14.7 39.8 ± 15.7 0.516
B. Appropriate ICD therapy SCD End stage HF death Total
2-year risk b 9% (n= 44) 3 0 0 3
6.8% 0.0% 0.0% 6.8%
Estimated number of cardiac death by 2-year risk model 2
2-year risk ≥ 9% (n= 54) 4 3 1 8
7.4% 5.6% 1.9% 14.8%
Estimated number of cardiac death by 2-year risk model 10
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Follow-up was complete for all 135 patients with a median follow-up
of 30 months (6–68 months). In total 34 patients experienced an event
during the course of the study. Six patients (4.4%) experienced more
than one cardiac event. Death from all causes occurred in 15 patients
(11.1%). Of these, 9 were cardiac deaths (6.7%), of which 5 were SCD
(none of them had prior non-fatal arrhythmias) and 4 due to terminal
heart failure. Seventeen patients (12.6%) received ICD therapy of whom
12 patients received appropriate therapy (i.e., ATP in 8 patients and
ICD shocks in 4 patients). Furthermore 6 patients were admitted to the
hospital due to HF progression.
For the analysis of the primary and secondary endpoint 24 patients
(17.8%) experienced a ﬁrst cardiac event during the course of the
study: appropriate ICD therapy (n=12), admission due to HF progres-
sion (n = 6), cardiac death (n = 6), consisting of SCD (n = 5) and
terminal heart failure (n= 1) (Fig. 1A and B).
A total of 98 patients had complete follow-up at 2 years. There was
agreement between the estimated and the actual events (2 vs. 3 in the
group with risk of b9% and 10 vs. 8 in the group with risk of ≥9%, be-
tween estimated and actual events, respectively) (Table 1B). Thereby
validating the mortality rate in our study population.There was an overlap in standardized late H/M ratio between the
patients with and without appropriate ICD therapy (Fig. 1C). Interest-
ingly, appropriate ICD therapy exclusively occurred in patients with
standardized late H/M ratios between 1.40 and 2.10. Fig. 2A shows
KaplanMeier curves for appropriate ICD therapy for different standard-
ized late H/M ratios. Multivariate Cox regression analysis showed no
independent predictors for appropriate ICD therapy. Univariate Cox
regression analysis showed that decreased standardized late H/M ratio
(HR 0.134 [0.035–0.515], p = 0.001) and increased WO (HR 1.062
[1.014–1.112], p = 0.010) were associated with the occurrence of the
combined endpoint. Multivariate Cox regression analysis showed that
only a decreased standardized late H/M ratio remained signiﬁcant as
an independent predictor of the combined endpoint (Table 2). Fig. 2B
shows Kaplan Meier curves for the combined endpoint for different
standardized late H/M ratios. Using the institutional (i.e. non standard-
ized) H/M ratios showed comparable results to standardized H/M ratio
(data not shown).
As the analysis for the primary endpoint did not show a statistical
signiﬁcant result, we used a post-hoc Cox regression analysis to predict
the freedom of appropriate ICD therapy. Univariate Cox regression analy-
sis showed that freedom of appropriate ICD therapy was associated with
increased LVEF (HR 1.045 [1.015–1.077], p = 0.003), decreased early
Fig. 1. A. Fraction of combined endpoint per tertile standardized late H/M ratio's.
B. Fraction of combined endpoint for different standardized late H/M ratio's. C. Boxplot
of standardized late H/M ratios for patients with and without appropriate ICD therapy
(p = 0.036). Green lines are mean values. The box plot indicates median, 25%, and 75%
quartile with whiskers for both ends.
Fig. 2. A. Kaplan Meier curves for appropriate ICD therapy for different standardized late
H/M ratio's. B. Kaplan Meier curves for combined endpoint for different standardized
late H/M ratio's.
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decreased standardized late H/M ratio (HR 0.533 [0.329–0.863], p =
0.009). In multivariate Cox regression analysis only LVEF and late H/M
ratio remained independent predictors of freedom of appropriate ICD
therapy (Table 2).4. Discussion
ICD implantation has become an integral component of contempo-
rary HF management.(3) Although the beneﬁts of ICD implantation
have been demonstrated in several randomized clinical trials, questions
have been raised if the current patient selection criteria are adequate. In
the MADIT II population only 35% of the patients received appropriate
ICD therapy during 3 years of follow-up.(4) Moreover, in about 15% of
patients with coronary artery disease, SCD is the ﬁrst manifestation of
underlying cardiac disease [19]. Even though LVEF b35% is most com-
monly used for risk stratiﬁcation for ventricular arrhythmias, it does
not adequately identify patients at risk for SCD. For example, arrhythmic
deaths occur also in populations with normal LVEF, but these patients
are not qualiﬁed for ICD implantation according to the current guide-
lines [20]. By contrast Shah et al. have shown that cardiac 123I-mIBGimaging provides prognostic information across a broad spectrum of
LVEFs [21].
The present study demonstrates that in stable CHF patients with
prophylactic ICD implantation none of the 123I-mIBG scintigraphy
derived parameters (standardized H/M ratios, 123I-mIBG WO, summed
SPECT score) was able to predict appropriate ICD therapy solely. The
lack of statistical power could be the effect of low number of included
subjects and consequently low cardiac event rate (i.e. appropriate ICD
therapy). Furthermore, in this contemporary study, modern ICD pro-
grammingwith longer detection times was used. This type of program-
ming could explain the relative small number of ICD therapy in the
current study compared to the results of the SCD-HeFT study. Finally,
41% of the included subjects received CRT, which may have improved
the LVEF and inﬂuenced cardiac sympathetic activity during follow-up
[22] and consequently could have reduced the cardiac event rate in
our study population.
In contrast to previous reported linear relationships between late
H/M ratio and overall prognosis, the results of the present study showed
a “bell-shape” curve for the late H/M ratio in relation to appropriated
ICD therapy (Fig. 1A and B). Patients with intermediate standardized
late H/M ratio (range 1.4–2.10) are more likely to have appropriate
ICD therapy compared to patients with low and high late H/M ratios.
These ﬁndings are in line with previous ﬁndings of Agostini et al. [23]
Arrhythmia occurred in patients with an intermediate late H/M ratio
between 1.46 and 2.17. In addition, Travin et al. concluded that the pre-
sumption of a monotonic increase in risk of an arrhythmic event with
increasing 123I-mIBG SPECT defects may not be correct. This conclusion
Table 2
Multivariate Cox regression analysis for freedom of appropriate ICD therapy and combined endpoint of ﬁrst cardiac events.
Variable HR (95% CI) χ2 Change χ2 p-Value
Combined endpoint Late H/M ratio 0.135 (0.035–0.517) 10.136 0.001
Free of appropriate ICD therapy LVEF Late
H/M ratio
1.052 (1.021–1.084)
0.461 (0.281–0.757)
18.461 8.567
9.894
b0.001
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intermediate defects on 123I-mIBG SPECT summed score appeared to be
at the highest risk for cardiac events [16]. This “bell-shape” curve could
have caused the lack of statistical power relationship between
123I-mIBG scintigraphy derived parameters and appropriated ICD thera-
py. However, post-hoc analysis showed that late H/M ratio and LVEF
were independent predictors for freedom of appropriated ICD therapy.
For the secondary endpoint, decreased late H/M ratiowas associated
with increased risk for the combined endpoint independent of LVEF and
NYHA functional class. This outcome is in linewith previous studies that
demonstrated the prognostic value of 123I-mIBG scintigraphy derived
parameters in CHF [23,24]. In addition, a meta-analysis has shown sim-
ilar results, but the majority of included studies were single centre [8].
The large multicentre ADMIRE-HF reported that decreased late H/M
ratio was associated with the composite endpoint of HF progression,
ventricular tachyarrhythmia and death, independent of LVEF and
brain natriuretic peptide (BNP) [7]. A predeﬁned LEHR collimator de-
rived late H/M ratio N 1.6was associatedwith an incidence of 1% cardiac
death per year while the annual cardiac mortality in a cohort with late
H/M level b 1.2 was almost 10 times higher (9.6%).
In addition to global cardiac sympathetic hyperactivity assessed
with 123I-mIBG scintigraphy there is evidence that in ischemic HF
regional innervation/perfusion mismatch with a larger defect size on
123I-mIBG SPECT than on myocardial perfusion imaging SPECT, predis-
pose to ventricular arrhythmias [25–27]. In a large prospective study
in 116 CHF patients, eligible for ICD implantation for both primary and
secondary prevention of SCD, 123I-mIBG SPECT was shown to be an in-
dependent predictor of appropriate ICD therapy and cardiac death
[12]. The cumulative incidence of appropriate ICD therapy during
3 years of follow-up was signiﬁcantly higher when a relatively large
123I-mIBG SPECT defect (median summed score ≥ 26) was present.
Similar results have been shown in a prospective PET study using 11C–
hydroxyephedrine for assessing sympathetic activity in ischemic heart
disease (n = 204), in which the innervation defect size predicted
cause-speciﬁc mortality from SCD independently of LVEF and infarct
volume [28].
In the present study the defect size of 123I-mIBG SPECT was large
(39.4 ± 15.5). However, there was no signiﬁcant difference between
patients with and without appropriated ICD therapy. Consequently,
123I-mIBG SPECT had no additional predictive value to planar 123I-
mIBG-derived parameters (i.e. late H/M ratio and 123I-mIBG WO). One
of the possible explanations for these ﬁndings could be the inclusion
of patients with both ischemic and non-ischemic HF, whereas in inner-
vation/perfusionmismatch studies only subjects with ischemic HFwere
included. However, the cause of HF (ischemic and non-ischemic) was
not associated with appropriate ICD therapy (data not shown).
The majority of patients who die of ventricular arrhythmia
have structural heart disease, predominately coronary artery disease.
Although the exact pathophysiology of ventricular arrhythmias is still
a matter of debate, it has been recognized that myocardial ischaemia
and scar tissue may serve as substrate for ventricular arrhythmias.
Areaswith slow conductionmay facilitate the development of reentrant
tachycardia [29]. Cardiac sympathetic hyperactivity is also an important
factor in the genesis of potential lethal ventricular arrhythmias in
patients with impaired LVEF. In these patients rhythm abnormalities
develop in relation to enhanced automaticity, triggered automaticity,
and reentrant mechanisms. Thesemechanisms are enhanced by releaseof norepinephrine (NE). In addition non-uniform denervatedmyocardi-
um in infarct zones can be hypersensitive to NE.30 Especially the border
zone of infarct tissue with viable myocardial tissue is predisposed to
develop reentrant circuits. This mechanism is most likely triggered by
the fact that sympathetic nerve ﬁbers aremore susceptible to ischaemia
than myocytes, thereby causing a disbalance between still viable but
partly denervated and normal myocardium [31,32]. This disbalance in
myocardial sympathetic innervation may create a myocardial substrate
particularly vulnerable to arrhythmia and arrhythmic death. The results
of the present studywith the “bell-shape” curve for the late H/M ratio in
relation to appropriated ICD therapy underlines this hypothesis.
Based on the results of previous studies, it has been suggested that
screening of guideline eligible CHF patients selected for ICDwith cardiac
123I-mIBG scintigraphymaybe cost effectivewith respect to ICD implan-
tation with minimal impact on survival [33]. Incorporating cardiac
123I-mIBG scintigraphy into the assessment of CHF patients eligible for
ICD implantation was associated with a 21% reduction in ICD utilization
[33]. Consequently, the number needed to screen to prevent 1 ICD
implantation is 5. Screening with 123I-mIBG imaging will reduce the
costs per patient with minimal losses of 0.001 and 0.040 life-years,
respectively, over 2 and 10 years.
Recently, the DANISH trial has shown that prophylactic ICD implan-
tation in patients with symptomatic non-ischemic systolic heart failure
was not associatedwith improved survival comparedwith usual clinical
care [34]. However, SCD occurred less often in the ICD group compared
to the control group (HR, 0.50; 95% CI, 0.31 to 0.82; p = 0.005). Most
likely the outcome of this study will change the indications for prophy-
lactic ICD implantation in non-ischemic CHF patients. Some non-
ischemic CHF patients remain at an increased risk for SCD. In line with
this ﬁnding, our study showed that despite optimal medical therapy
patients without ischemic heart disease still received appropriated ICD
therapy. Future studies will be needed to conﬁrm whether myocardial
123I-mIBG scintigraphy is helpful in speciﬁcally identifying non-ischemic
CHF patients with an increased SCD risk.
5. Study limitations
The most important limitation of this study is the small number of
included subjects. Despite increasing the number of participating insti-
tutions, the inclusion rate remained slow. The most important reasons
for this suboptimal inclusion rate were related to logistics reasons, not
given informed consent by subjects and competing studies. Further-
more, the relatively small event rate of appropriate ICD therapy may
have resulted in a limited statistical power. Therefore, the results should
be regarded as hypothesis-generating. In addition, the HF aetiology of
the enrolled patient population was heterogeneous including both
ischemic and non-ischemic HF. Therefore, additional studies are needed
to establish the speciﬁc role of 123ImIBG imaging in speciﬁc subpopula-
tions. Finally, 123I-mIBG SPECT imaging in patients with severe LV
dysfunction is frequently hampered by reduced myocardial tracer
uptake, resulting in poor-quality tomographic images.
In conclusion, planar myocardial 123I-mIBG scintigraphy derived late
H/M ratio and LVEF were associated with freedom of appropriate ICD
therapy. In addition there was a signiﬁcant association between late H/
M ratio and the combinedendpoint. Therefore, 123I-mIBG scintigraphy ap-
pears to be able tohelp selectingCHF subjectswhomight not beneﬁt from
an ICD implantation and therefore helps to constrain the HF related costs.
408 D.O. Verschure et al. / International Journal of Cardiology 248 (2017) 403–408Funding
This study was funded by a research grant from GE Healthcare B.V.
(grant number ADR-08-03).
Conﬂict of interest
K. Nakajima, MD, PhD has a collaboration to develop software with
FUJIFILM RI Pharma, Co. Ltd, Tokyo, Japan. All other authors (D.O.
Verschure, J.R. de Groot, S. Mirzaei, O. Gheysens, B.L. van Eck-Smit, G.A.
Somsen, H.J. Verberne) declare that they have no conﬂict of interest.
Appendix A
Participating local investigators (alphabetic order of institutions)
included:
D.O. Verschure, AcademicMedical Center, Amsterdam, the Netherlands,
V. Bongers, Diakonessenhuis, Utrecht, the Netherlands,
B.J. Krenning, Erasmus Medical Center, Rotterdam, the Netherlands,
N. Bijsterveld, Flevoziekenhuis, Almere, the Netherlands,
C. Bavelaar, Gelderse Vallei, Ede, the Netherlands,
I.H.M.L. D'hoore, Imelda ziekenhuis, Bonheiden, Belgium,
R.J.J. Knol, Noord West ziekenhuisgroep, Alkmaar, the Netherlands,
G.A. Somsen, OLVG oost, Amsterdam, the Netherlands,
F. Homans, Sint Augustinus, Wilrijk, Belgium,
A.J. Voogel, Spaarne Gasthuis, Hoofddorp, the Netherlands,
W. Jansen, Tergooi Ziekenhuis, Hilversum, the Netherlands,
S. Mirzaei, Wilhelminenspital, Vienna, Austria,
W. Mullens, Ziekenhuis Oost-Limburg, Genk, Belgium
References
[1] A.J.Moss,W. Zareba,W.J. Hall, H. Klein, et al., Prophylactic implantation of a deﬁbrillator
in patientswithmyocardial infarction and reduced ejection fraction,N. Engl. J.Med. 346
(2002) 877–883.
[2] S.J. Connolly, A.P. Hallstrom, R. Cappato, et al., Meta-analysis of the implantable
cardioverter deﬁbrillator secondary prevention trials. AVID, CASH and CIDS studies.
Antiarrhythmics vs Implantable Deﬁbrillator study. Cardiac Arrest Study Hamburg.
Canadian Implantable Deﬁbrillator Study, Eur. Heart J. 21 (2000) 2071–2078.
[3] P. Ponikowski, A.A. Voors, S.D. Anker, et al., 2016 ESC guidelines for the diagnosis
and treatment of acute and chronic heart failure: the task force for the diagnosis
and treatment of acute and chronic heart failure of the European Society of Cardiology
(ESC) developedwith the special contribution of the Heart Failure Association (HFA) of
the ESC, Eur. Heart J. 37 (2016) 2129–2200.
[4] A.J. Moss, H. Greenberg, R.B. Case, et al., Long-term clinical course of patients after
termination of ventricular tachyarrhythmia by an implanted deﬁbrillator, Circulation
110 (2004) 3760–3765.
[5] J.P. Daubert, W. Zareba, D.S. Cannom, et al., Inappropriate implantable cardioverter-
deﬁbrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival
impact, J. Am. Coll. Cardiol. 51 (2008) 1357–1365.
[6] D.M. Wieland, L.E. Brown, W. Les Rogers, et al., Myocardial imaging with a
radioiodinated norepinephrine storage analog, J. Nucl. Med. 22 (1981) 22–31.
[7] A.F. Jacobson, R. Senior, M.D. Cerqueira, et al., Myocardial iodine-123 meta-
iodobenzylguanidine imaging and cardiac events in heart failure. Results of the
prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart
Failure) study, J. Am. Coll. Cardiol. 55 (2010) 2212–2221.
[8] D.O. Verschure, C.E. Veltman, A. Manrique, et al., For what endpoint doesmyocardial
123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic
heart failure? Results of a pooled individual patient data meta-analysis, Eur Heart J
Cardiovasc Imaging. 15 (2014) 996–1003.
[9] F.J. Al Badarin, A.P.Wimmer, K.F. Kennedy, et al., The utility of ADMIRE-HF risk score
in predicting serious arrhythmic events in heart failure patients: incremental
prognostic beneﬁt of cardiac 123I-mIBG scintigraphy, J. Nucl. Cardiol. 21 (2014)
756–762.[10] D. Nagahara, T. Nakata, A. Hashimoto, et al., Predicting the need for an implantable
cardioverter deﬁbrillator using cardiac metaiodobenzylguanidine activity together
with plasma natriuretic peptide concentration or left ventricular function, J. Nucl.
Med. 49 (2008) 225–233.
[11] S. Tamaki, T. Yamada, Y. Okuyama, et al., Cardiac iodine-123metaiodobenzylguanidine
imaging predicts sudden cardiac death independently of left ventricular ejection
fraction in patients with chronic heart failure and left ventricular systolic dysfunction:
results from a comparative study with signal-averaged electrocardiogram, heart rate
variability, and QT dispersion, J. Am. Coll. Cardiol. 53 (2009) 426–435.
[12] M.J. Boogers, C.J.W. Borleffs, M.M. Henneman, et al., Cardiac sympathetic denervation
assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular
arrhythmias in implantable cardioverter-deﬁbrillator patients, J. Am. Coll. Cardiol. 55
(2010) 2769–2777.
[13] K. Nakajima, K. Okuda, M. Yoshimura, et al., Multicenter cross-calibration of I-123
metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-
collimator variations, J. Nucl. Cardiol. 21 (2014) 970–978.
[14] D.O. Verschure, E. Poel, K. Nakajima, et al., A European phantom study to cross-calibrate
myocardial 123I-mIBG scintigraphy, J. Nucl. Cardiol. (2017) 1–7.
[15] A. Flotats, I. Carrió, D. Agostini, et al., Proposal for standardization of 123I-
metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM
cardiovascular committee and the European Council of Nuclear Cardiology, Eur J
Nucl Med MolImaging. 37 (2010) 1802–1812.
[16] M.I. Travin, M.J. Henzlova, B.L. van Eck-Smit, et al., Assessment of I-mIBG and
Tc-tetrofosmin single-photon emission computed tomographic images for the pre-
diction of arrhythmic events in patients with ischemic heart failure: intermediate
severity innervation defects are associated with higher arrhythmic risk, J. Nucl.
Cardiol. 24 (2017) 377–391.
[17] T.A. Holly, B.G. Abbott, M. Al-Mallah, et al., Single photon-emission computed
tomography, J. Nucl. Cardiol. 17 (2010) 941–973.
[18] K. Nakajima, T. Nakata, S. Matsuo, et al., Creation of mortality risk charts using 123I
meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure:
2- and 5-year risk models, Eur Heart J Cardiovasc Imaging. 17 (2016) 1138–1145.
[19] W.B. Kannel, J.T. Doyle, P.M. McNamara, et al., Precursors of sudden coronary death.
Factors related to the incidence of sudden death, Circulation 51 (4) (1975) 606–613.
[20] R.J. Myerburg, K.M. Kessler, A. Castellanos, Sudden cardiac death. Structure, function,
and time-dependence of risk, Circulation 85 (1 Suppl) (1992) 2–10.
[21] A.M. Shah, M. Bourgoun, J. Narula, et al., Inﬂuence of ejection fraction on the
prognostic value of sympathetic innervation imaging with iodine-123 MIBG in
heart failure, JACC Cardiovascular imaging. 5 (2012) 1139–1146.
[22] A.M. Scholtens, A.J. Braat, A. Tuinenburg, et al., Cardiac sympathetic innervation and
cardiac resynchronization therapy, Heart Fail. Rev. 19 (2014) 567–573.
[23] D. Agostini, H.J. Verberne, W. Burchert, et al., I-123-mIBG myocardial imaging for
assessment of risk for a major cardiac event in heart failure patients: insights
from a retrospective European multicenter study, Eur. J. Nucl. Med. Mol. Imaging
35 (2008) 535–546.
[24] P. Merlet, C. Benvenuti, D. Moyse, et al., Prognostic value of MIBG imaging in
idiopathic dilated cardiomyopathy, J. Nucl. Med. 40 (1999) 917–923.
[25] M.V. Simoes, P. Barthel, I. Matsunari, et al., Presence of sympathetically denervated but
viable myocardium and its electrophysiologic correlates after early revascularised,
acute myocardial infarction, Eur. Heart J. 25 (2004) 551–557.
[26] T. Sasano, M.R. Abraham, K.C. Chang, et al., Abnormal sympathetic innervation of
viable myocardium and the substrate of ventricular tachycardia after myocardial
infarction, J. Am. Coll. Cardiol. 51 (2008) 2266–2275.
[27] A. Marshall, A. Cheetham, R.S. George, et al., Cardiac iodine-123
metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure
patients receiving an implantable cardioverter-deﬁbrillator for primary prevention,
Heart 98 (2012) 1359–1365.
[28] J.A. Fallavollita, B.M. Heavey, A.J. Luisi, et al., Regional myocardial sympathetic
denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy,
J. Am. Coll. Cardiol. 63 (2014) 141–149.
[29] J.M. de Bakker, F.J. van Capelle, M.J. Janse, et al., Slow conduction in the infarcted
human heart. 'Zigzag' course of activation, Circulation 88 (1993) 915–926.
[31] D.P. Zipes, Inﬂuence of myocardial ischemia and infarction on autonomic innervation
of heart, Circulation 82 (1990) 1095–1105.
[32] I. Matsunari, U. Schricke, F.M. Bengel, et al., Extent of cardiac sympathetic neuronal
damage is determined by the area of ischemia in patients with acute coronary
syndromes, Circulation 101 (2000) 2579–2585.
[33] K. O'Day, W.C. Levy, M. Johnson, et al., Cost-effectiveness analysis of iodine-123
meta-Iodobenzylguanidine imaging for screening heart failure patients eligible for
an implantable cardioverter deﬁbrillator in the USA, Appl Health Econ Health Policy.
14 (2016) 361–373.
[34] L. Kober, J.J. Thune, J.C. Nielsen, et al., Deﬁbrillator implantation in patients with
nonischemic systolic heart failure, N. Engl. J. Med. 375 (2016) 1221–1230.
